All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention GNTbm, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.8 across the same-window beat baseline. Their average consequence score of 7 runs above the beat's 5.8 for that window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about GNTbm-38
All 1 tracked stories fall under one category: regulation. Of the tracked stories, 1 of 1 also mention GNTbm, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.8 across the same-window beat baseline. Their average consequence score of 7 runs above the beat's 5.8 for that window. GNTbm-38 appears in 1 tracked Healthcare story from March 5, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 25 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering GNTbm-38. Shared-story counts are live from our verified record — not editorial picks.
The U.S. FDA has granted Investigational New Drug (IND) approval to GNTbm for its self-developed anti-cancer candidate, GNTbm-38. This milestone allows the company to initiate Phase I clinical trials in the United States, marking its transition into a clinical-stage biopharmaceutical entity.